

VANGUARD 7.

Authorised

- Leptospira interrogans, serovar Canicola, strain C51, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- Canine distemper virus, strain N-CDV, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine parvovirus, strain NL-35-D, Live

Product identification

Medicine name:

VANGUARD 7.

Active substance:

Leptospira interrogans, serovar Canicola, strain C51, Inactivated

Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

Canine distemper virus, strain N-CDV, Live

Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain NL-CPI-5, Live

Canine parvovirus, strain NL-35-D, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serovar Canicola, strain C51, Inactivated

740.00 unit(s) / 1.00 millilitre(s)

Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

915.00 unit(s) / 1.00 millilitre(s)

Canine distemper virus, strain N-CDV, Live

1000.00 50% cell culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan, Live

1584.89 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parainfluenza virus, strain NL-CPI-5, Live

1000000.00 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live

10000000.00 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and solvent for solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Available in:

Ireland

Package description:

The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-dried fraction are closed with a bromobutyl rubber stopper and a varnished aluminium

cap. Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and a varnished aluminium cap. Pack contains 100 vials of Vanguard DA2Pi freeze-dried fraction and 100 vials of 1 ml Vanguard CPV-L liquid fraction.

The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-dried fraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap. Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and a varnished aluminium cap. Pack contains 25 vials of Vanguard DA2Pi freeze-dried fraction and 25 vials of 1 ml Vanguard CPV-L liquid fraction.

The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-dried fraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap. Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and a varnished aluminium cap. Pack contains 10 vials of Vanguard DA2Pi freeze-dried fraction and 10 vials of 1 ml Vanguard CPV-L liquid fraction.

The vaccine is filled in 1 dose vials glass type I (Ph.Eur.). Vials of the freeze-dried fraction are closed with a bromobutyl rubber stopper and a varnished aluminium cap. Vials of the liquid fraction are closed with a chlorobutyl rubber stopper and a varnished aluminium cap. Pack contains 1 vial of Vanguard DA2Pi freeze-dried fraction and 1 vial of 1 ml Vanguard CPV-L liquid fraction.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium S.A.

Marketing authorisation date:

12/09/2014

Manufacturing sites for batch release:

Zoetis Belgium SA

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10387/082/001

Date of authorisation status change:

12/09/2014

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics